These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8622703)

  • 1. Inhibition of Bcr serine kinase by tyrosine phosphorylation.
    Liu J; Wu Y; Ma GZ; Lu D; Haataja L; Heisterkamp N; Groffen J; Arlinghaus RB
    Mol Cell Biol; 1996 Mar; 16(3):998-1005. PubMed ID: 8622703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase.
    Wu Y; Liu J; Arlinghaus RB
    Oncogene; 1998 Jan; 16(1):141-6. PubMed ID: 9467953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr phosphorylated on tyrosine 177 binds Grb2.
    Ma G; Lu D; Wu Y; Liu J; Arlinghaus RB
    Oncogene; 1997 May; 14(19):2367-72. PubMed ID: 9178913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
    Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
    Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
    Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
    Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
    Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
    Cortez D; Kadlec L; Pendergast AM
    Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
    Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
    Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.
    Muller AJ; Pendergast AM; Havlik MH; Puil L; Pawson T; Witte ON
    Mol Cell Biol; 1992 Nov; 12(11):5087-93. PubMed ID: 1383690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression with BCR induces activation of the FES tyrosine kinase and phosphorylation of specific N-terminal BCR tyrosine residues.
    Li J; Smithgall TE
    J Biol Chem; 1996 Dec; 271(51):32930-6. PubMed ID: 8955135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
    Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
    Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.
    Lu D; Liu J; Campbell M; Guo JQ; Heisterkamp N; Groffen J; Canaani E; Arlinghaus R
    Blood; 1993 Aug; 82(4):1257-63. PubMed ID: 8353288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.
    Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K
    Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
    McWhirter JR; Wang JY
    Mol Cell Biol; 1991 Mar; 11(3):1553-65. PubMed ID: 1705008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.